MA53917A - Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique - Google Patents
Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscariniqueInfo
- Publication number
- MA53917A MA53917A MA053917A MA53917A MA53917A MA 53917 A MA53917 A MA 53917A MA 053917 A MA053917 A MA 053917A MA 53917 A MA53917 A MA 53917A MA 53917 A MA53917 A MA 53917A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolo
- muscarinic receptor
- positive allosteric
- allosteric modulators
- pyridazine derivatives
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- YTJAMOLQXDNLJC-UHFFFAOYSA-N N1N=CC=C2N=CC=C21 Chemical class N1N=CC=C2N=CC=C21 YTJAMOLQXDNLJC-UHFFFAOYSA-N 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841039345 | 2018-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53917A true MA53917A (fr) | 2022-01-26 |
Family
ID=68470570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053917A MA53917A (fr) | 2018-10-17 | 2019-10-16 | Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12122779B2 (fr) |
| EP (1) | EP3867254B1 (fr) |
| JP (1) | JP7140915B2 (fr) |
| KR (1) | KR102607510B1 (fr) |
| CN (1) | CN113166160B (fr) |
| AU (1) | AU2019362468B2 (fr) |
| BR (1) | BR112021007168A2 (fr) |
| CA (1) | CA3116506C (fr) |
| EA (1) | EA202191046A1 (fr) |
| IL (1) | IL282336B (fr) |
| MA (1) | MA53917A (fr) |
| MX (1) | MX2021004471A (fr) |
| WO (1) | WO2020079606A1 (fr) |
| ZA (1) | ZA202102487B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ763341A (en) * | 2017-10-27 | 2023-03-31 | Suven Life Sciences Ltd | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101026819B1 (ko) * | 2003-01-09 | 2011-04-04 | 아스테라스 세이야쿠 가부시키가이샤 | 피롤로피리다진 유도체 |
| BR112012014180A2 (pt) | 2009-12-17 | 2015-09-15 | Merck Sharp & Dohme | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. |
| WO2011149801A1 (fr) | 2010-05-28 | 2011-12-01 | Merck Sharp & Dohme Corp. | Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1 |
| US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
| WO2015110370A1 (fr) | 2014-01-22 | 2015-07-30 | F. Hoffmann-La Roche Ag | Dérivés de fluoro-naphtyle |
| KR101730272B1 (ko) * | 2015-12-28 | 2017-04-26 | 씨제이헬스케어 주식회사 | 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제 |
| SMT202000554T1 (it) | 2016-09-02 | 2020-11-10 | Suven Life Sciences Ltd | Modulatori allosterici positivi del recettore muscarinico m1 |
| US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| WO2018194181A1 (fr) | 2017-04-18 | 2018-10-25 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques utiles en tant que modulateurs des récepteurs de l'acétylcholine |
| WO2019077517A1 (fr) * | 2017-10-18 | 2019-04-25 | Suven Life Sciences Limited | Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
-
2019
- 2019-10-16 MX MX2021004471A patent/MX2021004471A/es unknown
- 2019-10-16 EA EA202191046A patent/EA202191046A1/ru unknown
- 2019-10-16 BR BR112021007168-7A patent/BR112021007168A2/pt unknown
- 2019-10-16 JP JP2021521405A patent/JP7140915B2/ja active Active
- 2019-10-16 KR KR1020217014851A patent/KR102607510B1/ko active Active
- 2019-10-16 CN CN201980080853.1A patent/CN113166160B/zh active Active
- 2019-10-16 EP EP19798725.8A patent/EP3867254B1/fr active Active
- 2019-10-16 CA CA3116506A patent/CA3116506C/fr active Active
- 2019-10-16 AU AU2019362468A patent/AU2019362468B2/en active Active
- 2019-10-16 MA MA053917A patent/MA53917A/fr unknown
- 2019-10-16 WO PCT/IB2019/058815 patent/WO2020079606A1/fr not_active Ceased
- 2019-10-16 US US17/285,432 patent/US12122779B2/en active Active
-
2021
- 2021-04-14 IL IL282336A patent/IL282336B/en unknown
- 2021-04-15 ZA ZA2021/02487A patent/ZA202102487B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020079606A1 (fr) | 2020-04-23 |
| CA3116506C (fr) | 2023-08-01 |
| CA3116506A1 (fr) | 2020-04-23 |
| US20210340148A1 (en) | 2021-11-04 |
| AU2019362468B2 (en) | 2022-04-21 |
| JP7140915B2 (ja) | 2022-09-21 |
| MX2021004471A (es) | 2021-08-24 |
| KR102607510B1 (ko) | 2023-11-30 |
| AU2019362468A1 (en) | 2021-05-20 |
| ZA202102487B (en) | 2022-10-26 |
| BR112021007168A2 (pt) | 2021-08-10 |
| IL282336A (en) | 2021-05-31 |
| KR20210079320A (ko) | 2021-06-29 |
| IL282336B (en) | 2022-01-01 |
| US12122779B2 (en) | 2024-10-22 |
| WO2020079606A9 (fr) | 2020-08-13 |
| CN113166160B (zh) | 2023-12-19 |
| EA202191046A1 (ru) | 2021-07-12 |
| JP2022505401A (ja) | 2022-01-14 |
| CN113166160A (zh) | 2021-07-23 |
| EP3867254B1 (fr) | 2023-05-31 |
| EP3867254A1 (fr) | 2021-08-25 |
| NZ775905A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3864003T (lt) | Integruoto streso mechanizmo provaistų moduliatoriai | |
| EP3416639A4 (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
| MA49055A (fr) | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf | |
| MA49128A (fr) | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 | |
| HUE053586T2 (hu) | Muszkarin M1 receptor pozitív alloszterikus modulátorok | |
| EP3474846A4 (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| EP3347372A4 (fr) | Macrocycles peptidomimétiques en tant que modulateurs de mcl-1 | |
| EP3322415A4 (fr) | Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative | |
| MA52286A (fr) | Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine | |
| MA49126A (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| EP3654987A4 (fr) | Utilisation de dérivés aminoalkylbenzothiazépine | |
| EP3509588A4 (fr) | Composés bicycliques utiles en tant que modulateurs du gpr120 | |
| EP3534901A4 (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| MA47127A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| EP3758704A4 (fr) | Modulateurs de l'expression d'irf4 | |
| MA46899A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| DK3788043T3 (da) | Spiropiperidin som allosteriske modulatorer af nicotinacetylcholinreceptorer | |
| MA50464A (fr) | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| HUE063823T2 (hu) | Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként | |
| MA46461A (fr) | Sulfones tricycliques en tant que modulateurs de ror gamma | |
| HUE047056T2 (hu) | Fluoroindol-származékok mint muskarin M1 receptor pozitív alloszterikus modulátorok | |
| MA50402A (fr) | Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |